Heinz Christoph Maeusli net worth and biography

Heinz Maeusli Biography and Net Worth

Director of Lantheus

Heinz Mausli serves as Independent Director of the Company. Mr. Mäusli served on the board of directors of Progenics until the Effective Time. He brings more than 15 years of experience in the molecular nuclear medicine industry, as well as significant management and executive experience. Mr. Mäusli is the former Chief Financial Officer of Advanced Accelerator Applications S.A., previously serving on its board and also on the executive team that managed its integration into Novartis AG after helping it grow into a global leader within its field. He previously worked as a management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently. He is also a member of the board of Inventiva SA.

What is Heinz Christoph Maeusli's net worth?: The estimated net worth of Heinz Christoph Maeusli is at least $2.08 million as of May 28th, 2024. Mr. Maeusli owns 23,340 shares of Lantheus stock worth more than $2,084,029 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Maeusli may own. Learn More about Heinz Christoph Maeusli's net worth.
How do I contact Heinz Christoph Maeusli?: The corporate mailing address for Mr. Maeusli and other Lantheus executives is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. Lantheus can also be reached via phone at (978) 671-8001 and via email at [email protected]. Learn More on Heinz Christoph Maeusli's contact information.
Has Heinz Christoph Maeusli been buying or selling shares of Lantheus?: Heinz Christoph Maeusli has not been actively trading shares of Lantheus during the past quarter. Most recently, Heinz Christoph Maeusli sold 18,373 shares of the business's stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a transaction totalling $1,454,957.87. Following the completion of the sale, the director now directly owns 23,340 shares of the company's stock, valued at $1,848,294.60. Learn More on Heinz Christoph Maeusli's trading history.
Who are Lantheus' active insiders?: Lantheus' insider roster includes Minnie Baylor-Henry (Director), Gerard Ber (Director), Paul Blanchfield (Insider), John Bolla (COO), Michael Duffy (SVP), Mary Heino (CEO), Sam Leno (Director), Heinz Maeusli (Director), Brian Markison (CEO & Director), Robert Marshall, Jr. (CFO), Etienne Montagut (Insider), Daniel Niedzwiecki (Insider), Gary Pruden (Director), Andrea Sabens (CAO), and Carol Walker (SVP). Learn More on Lantheus' active insiders.
Are insiders buying or selling shares of Lantheus?: During the last year, Lantheus insiders bought shares 1 times. They purchased a total of 60,431,039 shares worth more than $57,409,487.05. During the last year, insiders at the medical equipment provider sold shares 13 times. They sold a total of 167,666 shares worth more than $12,647,453.05. The most recent insider tranaction occured on August, 12th when Director Gerard Ber sold 15,500 shares worth more than $1,495,440.00. Insiders at Lantheus own 1.5% of the company. Learn More about insider trades at Lantheus.
Information on this page was last updated on 8/12/2024.

Heinz Christoph Maeusli Insider Trading History at Lantheus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/28/2024	Sell	18,373	$79.19	$1,454,957.87	23,340
3/5/2021	Buy	1,000	$18.60	$18,600.00	16,211
1/29/2021	Buy	1,000	$16.13	$16,130.00	11,211
1/22/2021	Buy	1,000	$15.29	$15,290.00	10,211
1/15/2021	Buy	1,000	$15.80	$15,800.00	9,211

Heinz Christoph Maeusli Buying and Selling Activity at Lantheus

Lantheus Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Today's Range

Now: $89.29

$88.56

$91.69

50 Day Range

MA: $96.17

$76.22

$116.69

2 Week Range

Now: $89.29

$50.20

$126.89

Volume

2,181,956 shs

Average Volume

1,019,316 shs

Market Capitalization

$6.21 billion

P/E Ratio

14.86

Dividend Yield

N/A

Beta

0.45

Most People Are Dead Wrong.

From Brownstone Research | Ad

Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.